Deferasirox has been approved to treat patients 10 years and older with chronic iron overload from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT). Although NTDT is a milder form of thalassemia, patients are still at risk for organ damage caused by iron overload.  In clinical trials, the drug was shown to reduce liver iron concentrations to less than 5mg/g dry weight.  This new indication was approved through the FDA’s accelerated program.  What other medications have recently been approved by FDA’s accelerated approval process?

For more information, please visit FDA

 

Advertisements